Stocksigma LogoStocksigma Logo

Lord’s Mark Industries Outlines MedTech Expansion and Strong Multi-Year Growth Guidance

Lord’s Mark Industries provided FY27 guidance projecting consolidated revenue of ₹1,550 crore with ~21% EBITDA margin and ~13.25% PAT margin, led by

Lord’s Mark Industries Outlines MedTech Expansion and Strong Multi-Year Growth Guidance

Lords Mark Industries Ltd · Investor Presentation · 12 Sept 2026, 6:03 pm

Lord’s Mark Industries Outlines MedTech Expansion and Strong Multi-Year Growth Guidance Lord’s Mark Industries provided FY27 guidance projecting consolidated revenue of ₹1,550 crore with ~21% EBITDA margin and ~13.25% PAT margin, led by MedTech (₹825 crore). For FY28, revenue is targeted to cross ₹2,100 crore with EBITDA margins expanding to 23–24%. The firm plans ₹300–350 crore in capex over three years, including an IVD plant in Lucknow and in-house dialysis manufacturing. Operating cash flow is expected to turn positive in FY27. To meet MPS norms, promoters will dilute 4–5% via OFS and equity.

Original exchange filing (PDF)

More announcements from Lords Mark Industries Ltd

All Lords Mark Industries Ltd announcements